Copyright
©The Author(s) 2021.
World J Meta-Anal. Apr 28, 2021; 9(2): 139-152
Published online Apr 28, 2021. doi: 10.13105/wjma.v9.i2.139
Published online Apr 28, 2021. doi: 10.13105/wjma.v9.i2.139
Table 5 First-line recommended direct-acting antiviral therapies for hepatitis C patients
| Genotype | 1 | 2 | 3 | 4 | 5/6 |
| DAA schedule (non-cirrhotic) | Sofosbuvir/Ledipasvir; Or Glecaprevir/Pibrentasvir | Sofosbuvir/Velpatasvir | Sofosbuvir/Velpatasvir | Sofosbuvir/Ledipasvir | Sofosbuvir/Ledipasvir |
| Duration | 8-12 wk | 12 wk | 12 wk | 12 wk | 12 wk |
| DAA schedule (cirrhotic) | Sofosbuvir/Ledipasvir | Sofosbuvir/Velpatasvir | Glecaprevir/Pibrentasvir | Sofosbuvir/Ledipasvir | Sofosbuvir/Ledipasvir |
| Duration | 12 wk | 12 wk | 8-16 wk | 12 wk | 12 wk |
- Citation: Fagan O, Armstrong P, Merwe KVD, Crosnoi D, Steele C, Sopena-Falco J, Parihar V. Viral hepatitis: A brief introduction, review of management, advances and challenges. World J Meta-Anal 2021; 9(2): 139-152
- URL: https://www.wjgnet.com/2308-3840/full/v9/i2/139.htm
- DOI: https://dx.doi.org/10.13105/wjma.v9.i2.139